JP2013543853A5 - - Google Patents

Download PDF

Info

Publication number
JP2013543853A5
JP2013543853A5 JP2013538179A JP2013538179A JP2013543853A5 JP 2013543853 A5 JP2013543853 A5 JP 2013543853A5 JP 2013538179 A JP2013538179 A JP 2013538179A JP 2013538179 A JP2013538179 A JP 2013538179A JP 2013543853 A5 JP2013543853 A5 JP 2013543853A5
Authority
JP
Japan
Prior art keywords
chem
xaa
lys
histidine
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543853A (ja
JP6039569B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/069738 external-priority patent/WO2012062803A1/en
Publication of JP2013543853A publication Critical patent/JP2013543853A/ja
Publication of JP2013543853A5 publication Critical patent/JP2013543853A5/ja
Application granted granted Critical
Publication of JP6039569B2 publication Critical patent/JP6039569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538179A 2010-11-09 2011-11-09 二重アシル化されたglp−1誘導体 Active JP6039569B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10190515 2010-11-09
EP10190515.6 2010-11-09
US41422110P 2010-11-16 2010-11-16
US61/414,221 2010-11-16
EP11169276.0 2011-06-09
EP11169276 2011-06-09
US201161497123P 2011-06-15 2011-06-15
US61/497,123 2011-06-15
PCT/EP2011/069738 WO2012062803A1 (en) 2010-11-09 2011-11-09 Double-acylated glp-1 derivatives

Publications (3)

Publication Number Publication Date
JP2013543853A JP2013543853A (ja) 2013-12-09
JP2013543853A5 true JP2013543853A5 (enExample) 2014-11-06
JP6039569B2 JP6039569B2 (ja) 2016-12-07

Family

ID=46050422

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013538180A Active JP6231386B2 (ja) 2010-11-09 2011-11-09 リンカーを有する二重アシル化されたglp−1誘導体
JP2013538179A Active JP6039569B2 (ja) 2010-11-09 2011-11-09 二重アシル化されたglp−1誘導体
JP2016151098A Withdrawn JP2016188246A (ja) 2010-11-09 2016-08-01 リンカーを有する二重アシル化されたglp−1誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013538180A Active JP6231386B2 (ja) 2010-11-09 2011-11-09 リンカーを有する二重アシル化されたglp−1誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016151098A Withdrawn JP2016188246A (ja) 2010-11-09 2016-08-01 リンカーを有する二重アシル化されたglp−1誘導体

Country Status (6)

Country Link
US (3) US9006178B2 (enExample)
EP (2) EP2637698B1 (enExample)
JP (3) JP6231386B2 (enExample)
CN (3) CN103209711B (enExample)
ES (2) ES2913803T3 (enExample)
WO (2) WO2012062804A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
JP6231386B2 (ja) * 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
CN104039822A (zh) 2011-09-06 2014-09-10 诺沃—诺迪斯克有限公司 Glp-1衍生物
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Gip−glp−1デュアルアゴニスト化合物及び方法
JP6250034B2 (ja) 2012-05-08 2017-12-20 ノヴォ ノルディスク アー/エス 二重アシル化されたglp−1誘導体
EP2846824B1 (en) * 2012-05-08 2017-04-05 Novo Nordisk A/S Double-acylated glp-1 derivatives
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014199397A2 (en) * 2013-06-11 2014-12-18 Mylan Laboratories Ltd Process for the preparation of liraglutide
MX2015016564A (es) 2013-06-20 2016-04-15 Novo Nordisk As Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
KR20160029079A (ko) 2013-07-04 2016-03-14 노보 노르디스크 에이/에스 Glp-1 유사 펩티드의 유도체 및 그것의 사용
CN105451776B (zh) * 2013-08-15 2020-04-17 诺和诺德股份有限公司 Glp-1衍生物及其用途
CA2926314C (en) 2013-10-17 2023-08-29 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
US10221315B2 (en) * 2013-11-08 2019-03-05 Ppg Industries Ohio, Inc. Curable film-forming composition comprising catalyst associated with a carrier
EP3129041B1 (en) * 2014-04-07 2019-06-12 Novo Nordisk A/S Double-acylated glp-1 compounds
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
CN106999602B (zh) * 2014-11-27 2022-02-01 诺和诺德股份有限公司 Glp-1衍生物及其用途
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
CA2980978A1 (en) 2015-04-16 2016-10-20 Zealand Pharma A/S Acylated glucagon analogue
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2019023295A1 (en) * 2017-07-27 2019-01-31 Saint Louis University Fatty acid modified human epidermal growth factor
JP6633777B2 (ja) 2017-08-24 2020-01-22 ノヴォ ノルディスク アー/エス Glp−1組成物及びその使用
DK3774862T3 (da) 2018-04-05 2022-09-05 Sun Pharmaceutical Ind Ltd Nye GLP-1-analoger
CN113214382B (zh) * 2018-04-19 2024-01-19 杭州先为达生物科技股份有限公司 酰化的glp-1衍生物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
AU2021208601B2 (en) 2020-02-18 2025-06-05 Novo Nordisk A/S Glp-1 compositions and uses thereof
KR20230083294A (ko) 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법
WO2022096636A1 (en) * 2020-11-06 2022-05-12 Novo Nordisk A/S Glp-1 prodrugs and uses hereof
CN117279657A (zh) 2021-05-18 2023-12-22 日本株式会社Ltt生物医药 用于治疗或预防伴随抗癌剂给药的障碍的医药组合物
WO2022266927A1 (zh) * 2021-06-24 2022-12-29 深圳翰宇药业股份有限公司 一种利拉鲁肽变构体及其制备方法、应用
CA3252113A1 (en) 2022-03-30 2023-10-05 Beijing Ql Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use
CN119173275A (zh) 2022-05-10 2024-12-20 诺和诺德股份有限公司 Glp-1多肽的前药及其用途
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
CN120676965A (zh) * 2023-11-07 2025-09-19 深圳信立泰药业股份有限公司 多重受体共激动剂化合物及其制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
SE9102652D0 (sv) * 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Glp―1誘導体
AU2610699A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S Derivatives of glp-1 analogs
MY155270A (en) * 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 glp-1 유도체
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー/エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
EP2190460B1 (en) * 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2195034A2 (en) * 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
JP2013514322A (ja) * 2009-12-16 2013-04-25 ノヴォ ノルディスク アー/エス 修飾されたn末端を有するglp−1受容体アゴニスト化合物
JP6231386B2 (ja) * 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体

Similar Documents

Publication Publication Date Title
JP2013543853A5 (enExample)
JP2014501712A5 (enExample)
JP2014529629A5 (enExample)
RU2013148921A (ru) Дважды ацилированные производные glp-1
JP2015517478A5 (enExample)
JP2015517477A5 (enExample)
JP2017514801A5 (enExample)
JP2010538049A5 (enExample)
JP2016523243A5 (enExample)
JP2018506507A5 (enExample)
JP2016529253A5 (enExample)
JP2017105819A5 (enExample)
JP2008533105A5 (enExample)
JP2013517307A5 (enExample)
JP2018505859A5 (enExample)
KR102505628B1 (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
JP2012506402A5 (enExample)
JP2016526012A5 (enExample)
EP3634468B1 (en) Solid compositions for oral administration
JP2014503526A5 (enExample)
JP2013525387A (ja) Glp−1受容体作動薬とガストリンとのペプチド複合体及びその使用
JP2007519642A5 (enExample)
JP2008533104A (ja) Glp−1受容体の二量体ペプチドアゴニスト
JP2014510739A5 (enExample)
JP2005528337A5 (enExample)